SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Ionis Pharmaceuticals (IONS)
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
4676 121 0 IONS
Emcee:  Keith Fauci Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3226<i>including</i> <b>principle</b> Amazing that the cfotom pope-4/24/2002
3225Isis Pharmaceuticals to Make Early Payment of $74 Million of 14% Senior SubordinSemiBull-4/24/2002
3224Isis Pharmaceuticals Reports First Quarter 2002 Highlights and Financial ResultsSemiBull-4/23/2002
3223The $125 million convertible announcement took about $80 million off the market Elmer-4/23/2002
3222nope <i>Related Quote ISIS 15.21 -1.481 delayed 20 mins - disclaimer Qutom pope-4/23/2002
3221What is the conversion price? Did they announce that?Kushi Kullar-4/23/2002
3220From Briefing: ISIS Pharm announces $125 convertible offering (15.35 -1.34) Actom pope-4/23/2002
3219Isis Pharmaceuticals and Merck Extend Hepatitis C Drug Discovery Collaboration fSemiBull-4/22/2002
3218biz.yahoo.comElmer-4/22/2002
3217Isis Pharmaceuticals and Lilly's Strategic Alliance Voted Breakthrough AlliaSemiBull-4/11/2002
3216Isis Pharmaceuticals Reports Preliminary Phase II Data On ISIS 2503 Plus ChemothSemiBull-4/10/2002
3215Isis Pharmaceuticals' Ibis Therapeutics Division Awarded New $2.4 Million GoSemiBull-4/4/2002
3214Issuance of Key Second-Generation Antisense Patent Further Strengthens Isis'nigel bates-4/3/2002
3213OncoGenex Appoints Mr. James F. Shepard, Dr. Julia Levy and Mr. Richard M. GlickSemiBull-4/2/2002
3212Isis Pharmaceuticals Announces Adoption of Securities Trading Plan Under SEC RulSemiBull-4/2/2002
3211Full press release..... Isis Pharmaceuticals' GeneTrove Division Enters IntSemiBull-3/27/2002
3210We have another collaboration, this one with Pharmacia. With all the positive suElmer-3/27/2002
3209HepaSense Initiates Phase II Clinical Trial of ISIS 14803 in Hepatitis C CARLSBSemiBull-3/21/2002
3208ON24: Phase II rheumatoid arthritis trial for Isis-104838 biz.yahoo.comSemiBull-3/18/2002
3207Isis Pharmaceuticals Initiates Phase II Clinical Trial of ISIS 104838, A TNF-AlpSemiBull-3/13/2002
3206Dr. John C. Reed Elected to Isis Pharmaceuticals' Board of Directors CARLSBSemiBull-2/26/2002
3205Full press release..... Isis Pharmaceuticals Reports Phase II Study Results Of SemiBull-2/25/2002
3204Time and patience needed....if it wasn't, things would be too easy, sort of SemiBull-2/25/2002
3203The heartbreak of psoriasis trials? <g> You would think this stock and theElmer-2/25/2002
3202Isis Psoriasis Results Weak story.news.yahoo.com By Deena Beasley LOS ANGELSemiBull-2/24/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News